Folic Acid-Doxorubicin-Double-Functionalized-Lipid-Core Nanocapsules : Synthesis, Chemical Structure Elucidation, and Cytotoxicity Evaluation on Ovarian (OVCAR-3) and Bladder (T24) Cancer Cell Lines
PURPOSE: Folic acid-doxorubicin-double-functionalized-lipid-core nanocapsules (LNC-CS-L-Zn+2-DOX-FA) were prepared, characterized, and evaluated in vitro against ovarian and bladder cancer cell lines (OVCAR-3 and T24).
METHODS: LNC-CS-L-Zn+2-DOX-FA was prepared by self-assembly and interfacial reactions, and characterized using liquid chromatography, particle sizing, transmission electron microscopy, and infrared spectroscopy. Cell viability and cellular uptake were studied using MTT assay and confocal microscopy.
RESULTS: The presence of lecithin allows the formation of nanocapsules with a lower tendency of agglomeration, narrower size distributions, and smaller diameters due to an increase in hydrogen bonds at the surface. LNC-L-CS-Zn+2-DOX-FA, containing 98.00 ± 2.34 μg mL-1 of DOX and 105.00 ± 2.05 μg mL-1 of FA, had a mean diameter of 123 ± 4 nm and zeta potential of +12.0 ± 1.3 mV. After treatment with LNC-L-CS-Zn+2-DOX-FA (15 μmol L-1 of DOX), T24 cells had inhibition rates above 80% (24 h) and 90% (48 h), whereas OVCAR-3 cells showed inhibition rates of 68% (24 h) and 93% (48 h), showing higher cytotoxicity than DOX.HCl. The fluorescent-labeled formulation showed a higher capacity of internalization in OVCAR-3 compared to T24 cancer cells.
CONCLUSION: Lecithin favored the increase of hydrogen bonds at the surface, leading to a lower tendency of agglomeration for nanocapsules. LNC-CS-L-Zn+2-DOX-FA is a promising therapeutic agent against tumor-overexpressing folate receptors.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:38 |
|---|---|
| Enthalten in: |
Pharmaceutical research - 38(2021), 2 vom: 19. Feb., Seite 301-317 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Cé, Rodrigo [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
80168379AG |
|---|
| Anmerkungen: |
Date Completed 18.10.2021 Date Revised 18.10.2021 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1007/s11095-021-02989-y |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM321675134 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM321675134 | ||
| 003 | DE-627 | ||
| 005 | 20231225180402.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s11095-021-02989-y |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1072.xml |
| 035 | |a (DE-627)NLM321675134 | ||
| 035 | |a (NLM)33608808 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Cé, Rodrigo |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Folic Acid-Doxorubicin-Double-Functionalized-Lipid-Core Nanocapsules |b Synthesis, Chemical Structure Elucidation, and Cytotoxicity Evaluation on Ovarian (OVCAR-3) and Bladder (T24) Cancer Cell Lines |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 18.10.2021 | ||
| 500 | |a Date Revised 18.10.2021 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a PURPOSE: Folic acid-doxorubicin-double-functionalized-lipid-core nanocapsules (LNC-CS-L-Zn+2-DOX-FA) were prepared, characterized, and evaluated in vitro against ovarian and bladder cancer cell lines (OVCAR-3 and T24) | ||
| 520 | |a METHODS: LNC-CS-L-Zn+2-DOX-FA was prepared by self-assembly and interfacial reactions, and characterized using liquid chromatography, particle sizing, transmission electron microscopy, and infrared spectroscopy. Cell viability and cellular uptake were studied using MTT assay and confocal microscopy | ||
| 520 | |a RESULTS: The presence of lecithin allows the formation of nanocapsules with a lower tendency of agglomeration, narrower size distributions, and smaller diameters due to an increase in hydrogen bonds at the surface. LNC-L-CS-Zn+2-DOX-FA, containing 98.00 ± 2.34 μg mL-1 of DOX and 105.00 ± 2.05 μg mL-1 of FA, had a mean diameter of 123 ± 4 nm and zeta potential of +12.0 ± 1.3 mV. After treatment with LNC-L-CS-Zn+2-DOX-FA (15 μmol L-1 of DOX), T24 cells had inhibition rates above 80% (24 h) and 90% (48 h), whereas OVCAR-3 cells showed inhibition rates of 68% (24 h) and 93% (48 h), showing higher cytotoxicity than DOX.HCl. The fluorescent-labeled formulation showed a higher capacity of internalization in OVCAR-3 compared to T24 cancer cells | ||
| 520 | |a CONCLUSION: Lecithin favored the increase of hydrogen bonds at the surface, leading to a lower tendency of agglomeration for nanocapsules. LNC-CS-L-Zn+2-DOX-FA is a promising therapeutic agent against tumor-overexpressing folate receptors | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a OVCAR-3: ovarian cancer line | |
| 650 | 4 | |a T24: bladder cancer line | |
| 650 | 4 | |a doxorubicin | |
| 650 | 4 | |a folic acid | |
| 650 | 4 | |a lipid-core nanocapsules | |
| 650 | 7 | |a Drug Carriers |2 NLM | |
| 650 | 7 | |a Lecithins |2 NLM | |
| 650 | 7 | |a Nanocapsules |2 NLM | |
| 650 | 7 | |a Doxorubicin |2 NLM | |
| 650 | 7 | |a 80168379AG |2 NLM | |
| 650 | 7 | |a Folic Acid |2 NLM | |
| 650 | 7 | |a 935E97BOY8 |2 NLM | |
| 700 | 1 | |a Lavayen, Vladimir |e verfasserin |4 aut | |
| 700 | 1 | |a Couto, Gabriela Klein |e verfasserin |4 aut | |
| 700 | 1 | |a De Marchi, João Guilherme Barreto |e verfasserin |4 aut | |
| 700 | 1 | |a Pacheco, Barbara Zoche |e verfasserin |4 aut | |
| 700 | 1 | |a Natividade, Letícia Antunes |e verfasserin |4 aut | |
| 700 | 1 | |a Fracari, Tiago Ost |e verfasserin |4 aut | |
| 700 | 1 | |a Ciocheta, Taiane Medeiro |e verfasserin |4 aut | |
| 700 | 1 | |a de Cristo Soares Alves, Aline |e verfasserin |4 aut | |
| 700 | 1 | |a Jornada, Denise Soledade |e verfasserin |4 aut | |
| 700 | 1 | |a Guterres, Silvia Stanisçuaski |e verfasserin |4 aut | |
| 700 | 1 | |a Seixas, Fabiana |e verfasserin |4 aut | |
| 700 | 1 | |a Collares, Tiago |e verfasserin |4 aut | |
| 700 | 1 | |a Pohlmann, Adriana Raffin |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Pharmaceutical research |d 1984 |g 38(2021), 2 vom: 19. Feb., Seite 301-317 |w (DE-627)NLM012597236 |x 1573-904X |7 nnns |
| 773 | 1 | 8 | |g volume:38 |g year:2021 |g number:2 |g day:19 |g month:02 |g pages:301-317 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1007/s11095-021-02989-y |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 38 |j 2021 |e 2 |b 19 |c 02 |h 301-317 | ||